Google
Trusted Resources: News & Events
Latest announcements and gatherings
Hydroxyurea linked to ‘significant, rapid’ reduction of sperm count
Six months of hydroxyurea therapy detrimentally effected spermatogenesis in men with sickle cell anemia, according to a small prospective study published in Blood.
“Hydroxyurea, at current doses, causes significant, rapid and unpredictable impairment of spermatogenesis in treated men,” Isabelle Berthaut, PhD, professor of histology and biology of reproduction at Tenon Hospital in Paris, and colleagues wrote.
Hydroxyurea — approved by the FDA in 1998 for the treatment of sickle cell anemia — helps reduce the production of sickle hemoglobin. Its side effects include low blood counts, gastrointestinal symptoms and loss of appetite.
Three previous retrospective studies showed an association between hydroxyurea and potentially detrimental effects on sperm parameters in men with sickle cell anemia. However, those observations occurred on studies involving as few as eight men, seven of whom did not have any comparative semen assessment prior to hydroxyurea initiation.
+myBinderRelated Content
-
Sickle Cell Disease, Hydroxyurea: What You Should Knowhttps://www.onescdvoice.com/wp-content/u...
-
Aisha Walker, PhDDr. Walker is a Research Assistant Profe...
-
Sickle Cell Carriers’ Unmet Information Needs: Beyond Knowing Trait StatusBenefits of identifying sickle cell dise...
-
Hydroxyurea for Children – A HRSA EMBRACE Projecthttps://www.youtube.com/watch?v=LprBMpPb...
-
FertilityIf you might want to have children in th...
-
Hydroxyurea Treatment for Children with Sickle Cell Diseasehttps://www.youtube.com/watch?v=nx7MvMje...
-
Developing Hydroxyurea, the First FDA-Approved Therapy for Sickle Cell Diseasehttps://www.youtube.com/watch?v=0kIz5ZKy...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.